PD-L1 Testing and Clinical Benefit in Patients Treated with CPI

被引：1
|
作者：
Kovacevic, M. [1 ]
Ivanovic, M. [1 ]
Kern, I. [1 ]
Cufer, T. [1 ]
机构：
[1] Univ Clin Golnik, Pathol, Golnik, Slovenia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
PD-L1; CPI; NSCLC;
D O I：
10.1016/j.jtho.2019.08.1679
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-30
引用
收藏
页码：S781 / S782
页数：3
相关论文
共 50 条
  • [1] PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
    Minari, Roberta
    Bonatti, Francesco
    Mazzaschi, Giulia
    Dodi, Alessandra
    Facchinetti, Francesco
    Gelsomino, Francesco
    Cinquegrani, Gloria
    Squadrilli, Anna
    Bordi, Paola
    Buti, Sebastiano
    Bersanelli, Melissa
    Leonetti, Alessandro
    Cosenza, Agnese
    Ferri, Leonarda
    Rapacchi, Elena
    Quaini, Federico
    Ardizzoni, Andrea
    Tiseo, Marcello
    [J]. TUMORI JOURNAL, 2022, 108 (01): : 47 - 55
  • [2] The Clinical Implications of Soluble PD-L1 in Hepatocellular Carcinoma Patients Treated With Radiation Therapy
    Kim, H. J.
    Park, S.
    Kim, K. J.
    Seong, J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S89 - S89
  • [3] Clinical significance of soluble PD-L1 level in hepatocellular carcinoma patients treated with RT
    Kim, H. J.
    Park, S.
    Kim, K. J.
    Seong, J.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S21 - S22
  • [4] Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
    Zhang, Jie
    Gao, Jing
    Li, Yanyan
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Chen, Xiaoling
    Han, Jindi
    Ma, Xiangjuan
    Tian, Guangming
    Wu, Di
    Shen, Lin
    Fang, Jian
    [J]. THORACIC CANCER, 2015, 6 (04) : 534 - 538
  • [5] Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy
    Hwang, William L.
    Niemierko, Andrzej
    Hwang, Katie L.
    Hubbeling, Harper
    Schapira, Emily
    Gainor, Justin F.
    Keane, Florence K.
    [J]. JAMA ONCOLOGY, 2018, 4 (02) : 253 - 255
  • [6] Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors
    Li, Zhiyang
    Wu, Xin
    Zhao, Yanjie
    Xiao, Yinan
    Zhao, Yunuo
    Zhang, Ting
    Li, Hui
    Sha, Fushen
    Wang, Yating
    Deng, Lei
    Ma, Xuelei
    [J]. MEDCOMM, 2021, 2 (01): : 60 - 68
  • [7] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [8] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Hidetomo Himuro
    Yoshiro Nakahara
    Yuka Igarashi
    Taku Kouro
    Naoko Higashijima
    Norikazu Matsuo
    Shuji Murakami
    Feifei Wei
    Shun Horaguchi
    Kayoko Tsuji
    Yasunobu Mano
    Haruhiro Saito
    Koichi Azuma
    Tetsuro Sasada
    [J]. Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
  • [9] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
    Nakahara, Y.
    Himuro, H.
    Igarashi, Y.
    Kouro, T.
    Higashijima, N.
    Matsuo, N.
    Murakami, S.
    Wei, F.
    Horaguchi, S.
    Tsuji, K.
    Mano, Y.
    Saito, H.
    Azuma, K.
    Naoki, K.
    Sasada, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
  • [10] PD-L1 testing in gastric cancer
    Ushiku, Tetsuo
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1361 - S1361
12345